FindMyKOL
Clinical trialNCT04545424RecruitingPhase 2Interventional

Trial of Therapeutic Hypothermia in Patients With ARDS

SponsorUniversity of Maryland, BaltimoreEnrollment340Respiratory Distress Syndrome, Adult
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of \~40%, and has no known treatment other than optimization of support. Data from basic research, animal models, and retrospective studies, case series, and small prospective studies suggest that therapeutic hypothermia (TH) similar to that used for cardiac arrest may be lung protective in patients with ARDS; however, shivering is a major complication of TH, often requiring paralysis with neuromuscular blocking agents (NMBA) to control. Since the recently completed NHLBI PETAL ROSE trial showed that NMBA had no effect (good or bad) in patients with moderate to severe ARDS, the CHILL trial is designed to evaluate whether TH combined with NMBA is beneficial in patients with ARDS. This Phase IIb randomized clinical trial is funded by the Department of Defense to compare TH (core temperature 34-35°C) + NMBA for 48h vs. usual temperature management in patients in 14 clinical centers with the Clinical Coordination Center and Data Coordinating Center at University of Maryland Baltimore. Planned enrollment is 340 over \~3.5 years of the 4-year contract. COVID-19 is considered an ARDS risk-factor and patients with ARDS secondary to COVID-19 pneumonia will be eligible for enrollment. Primary outcome is 28-day ventilator-free days. Secondary outcomes include safety, physiologic measures, mortality, hospital and ICU length of stay, and serum biomarkers collected at baseline and on days 1, 2, 3, 4, and 7.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Cedars-Sinai Medical Center

    Los Angeles, California, United States

  • Yale University

    New Haven, Connecticut, United States

  • Emory University

    Atlanta, Georgia, United States

  • Loyola University Chicago

    Chicago, Illinois, United States

  • Rush University Medical Center

    Chicago, Illinois, United States

  • University of Kentucky

    Lexington, Kentucky, United States

  • Johns Hopkins Hospital

    Baltimore, Maryland, United States

  • University of Maryland Medical Center

    Baltimore, Maryland, United States

  • Henry Ford Hospital

    Detroit, Michigan, United States

  • Cooper Health System

    Camden, New Jersey, United States

  • University of Cincinnati

    Cincinnati, Ohio, United States

  • Cleveland Clinc

    Cleveland, Ohio, United States

  • Oregon Health & Science University

    Portland, Oregon, United States

  • Temple University

    Philadelphia, Pennsylvania, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, United States

  • University of Pennsylavia

    Philadelphia, Pennsylvania, United States

  • Brooke Army Medical Center

    Fort Sam Houston, Texas, United States

  • Intermountain Healthcare (utah)

    Salt Lake City, Utah, United States

  • University of Wisconsin

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Neuromuscular Blocking Agents
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
29 Jun 2021
Primary completion
30 Jun 2026
Completion
30 Sept 2026
Last update posted
9 Sept 2026
Registered enrollment
340
Registry id
NCT04545424

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.